Skip to main content

Table 2 Hematological and organ responses

From: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

ITT Months post HDM/SCT
3 3 12 12 24 24
BD + HDM/SCT HDM/SCT BD + HDM/SCT HDM/SCT BD + HDM/SCT HDM/SCT
  Number = 28 Number = 28 Number = 28 Number = 28 Number = 20 Number = 23
CR 15 (53.6%)a 6 (21.4%) 19 (67.9%)a 10 (35.7%) 14 (70%)a 8 (34.8%)
VGPR 4 (14.3%) 4 (14.3%) 2 (7.1%) 3 (10.7%) 1 (5%) 1(4.3%)
PR 3 (10.7%) 4 (14.3%) 3 (10.7%) 2(2.1%) 1 (5%) 2 (8.7%)
NR 6 (21.4%) 12 (42.8%) 2 (7.1%) 6 (21.4%) 2 (10%) 3 (13.0%)
PD - - 2 (7.1%) 3 (10.7%) 1 (5%) 3 (13.0%)
Organ responses
Kidneyb    65.2% (15/23) 39.1% (9/23) 75% (12/16) 53.8% (7/13)
Heartb    67% (10/15) 25% (4/12) 70% (7/10) 50% (3/6)
Liverb    100% (1/1) 50% (1/2) 100% (1/1) 100% (1/1)
NSb    100% (3/3) 100% (2/2) 100% (3/3) 100% (2/2)
  1. aCompared with the HDM/SCT group, P <0.05; bevaluable patients. CR, complete hematological response; ITT, intention-to-treat; NR, no response; NS, nervous system; PD, disease progression; PR, partial response; SD, stable disease; VGPR, very good partial response.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us

\